- |||||||||| ceftriaxone / Generic mfg., levofloxacin / Generic mfg., azithromycin / Generic mfg.
THE CHALLENGES FACED WHEN TREATING HOSPITALIZED PATIENTS WITH LEGIONNAIRE'S DISEASE (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1220;
The above case demonstrates the challenge of identifying patients who may progress to severe disease and the need for evidence based predictive models to help clinicians identify these high risk patients. More research needs to be carried out in identifying local resistance patterns and antibiotic susceptibility, as this may improve outcomes once diagnosis is made.
- |||||||||| SECOND TIME'S THE CHARM: PULMONARY NOCARDIOSIS IN AN IMMUNOCOMPETENT PATIENT (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1218;
She had been diagnosed with several URI and bronchitis episodes and was treated with multiple 5-day courses of antibiotics including augmentin, azithromycin, cefdinir, doxycycline, and levofloxacin...She is currently on bactrim and follows with pulmonology and infectious disease outpatient... Our case highlights the importance of considering atypical infections including Nocardia in the differential for refractory cough in an immunocompetent patient.
- |||||||||| levofloxacin / Generic mfg., olanzapine/fluoxetine / Generic mfg.
LEGIONELLA TRIAD: A RARE PRESENTATION OF LEGIONNAIRES' DISEASE (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1173;
This case report highlights a distinct presentation of legionnaires disease associated rhabdomyolysis and acute renal failure and the need to maintain a high degree of suspicion for legionella pneumonia even in patients without classic symptoms like fever, especially for high-risk individuals like those residing in shelters. Our patient was successfully treated with aggressive hydration and appropriate antibiotics and didn't require initiation of hemodialysis, emphasizing the need for early recognition and prompt initiation of treatment.
- |||||||||| levofloxacin / Generic mfg.
MULTIDRUG-RESISTANT PSEUDOMONAS PNEUMONIA IN NON-CYSTIC FIBROSIS BRONCHIECTASIS (Convention Center Exhibit Hall: Poster Area 1) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1097;
Acute exacerbations of bronchiectasis stimulate ongoing neutrophilic airway inflammation, resulting in progressive lung damage, lung function decline, and worsened quality of life. Pseudomonas colonization plays a significant role in the progression of disease.
- |||||||||| Trikafta (elexacaftor/tezacaftor/ivacaftor) / Vertex
COMPLETE PHRENIC NERVE PARALYSIS IN A PATIENT WITH CYSTIC FIBROSIS (Convention Center Exhibit Hall: Poster Area 1) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1096;
DP is rare in CF patients. Plication surgery can be an effective and successful treatment option for DP in CF patients with complete phrenic nerve paralysis confirmed by EMG.
- |||||||||| ceftriaxone / Generic mfg., levofloxacin / Generic mfg., meropenem / Generic mfg.
Journal: Quahogging in a Marine Habitat: An Extremely Rare Source of an Organism to Cause Endocarditis. (Pubmed Central) - Jul 30, 2024
He was monitored through transthoracic echocardiography as he continued medical management with levofloxacin 750 mg daily. Six months after his discharge from the hospital he developed worsening heart failure and elected to pursue comfort measures only.
- |||||||||| Journal: Occurrence of antimicrobial-resistant bovine mastitis bacteria in Sakon Nakhon, Thailand. (Pubmed Central) - Jul 30, 2024
Tetracycline (TET) and macrolide-resistant genes of Streptococcus spp...Antibiotic susceptibility tests revealed the following resistance profiles to bacterial species: TET (85.92%), clindamycin (29.58%), erythromycin (15.49%), levofloxacin (14.08%), and penicillin (0%)...pneumoniae [8.33%], Klebsiella variicola [2.38%], Klebsiella quasipneumoniae [1.19%], and Escherichia coli [1.19%]) were recovered and still susceptible to meropenem (100%), ceftazidime (97.06%), ceftriaxone (79.41%), and ciprofloxacin (79.41%)...In this study, limited data were available including one from small-holder dairy farms and study only dairy farms in Sakon Nakhon, Thailand. So, more farms should be included in the future studies.
- |||||||||| levofloxacin / Generic mfg.
Journal: Fluoroquinolone Prophylaxis in Children with Cancer: A Pro/Con Discussion. (Pubmed Central) - Jul 29, 2024
The nuance for the decision to give or not give prophylaxis are discussed in the context of published evidence defining the risks and benefits of levofloxacin prophylaxis for pediatric leukemia patients at high risk for bacterial infection. Knowledge gaps are also identified to guide further investigations to optimize the use of fluoroquinolone prophylaxis in pediatric patients receiving chemotherapy for cancer or undergoing a hematopoietic cell transplantation.
- |||||||||| Journal: Occurrence of Enterococci in the Process of Artisanal Cheesemaking and Their Antimicrobial Resistance. (Pubmed Central) - Jul 27, 2024
A PCR analysis of vanA (4.41%) and tetM (14.71%) revealed that antimicrobial resistance genes were present in not only phenotypic resistant isolates of enterococci but also susceptible isolates. The investigation of antimicrobial resistance in enterococci during the cheesemaking process can be a source of valuable information for public health in the concept of "One Health".
- |||||||||| Journal: Drug-Resistant Profiles and Genetic Diversity of Mycobacterium Tuberculosis Revealed by Whole-Genome Sequencing in Hinggan League of Inner Mongolia, China. (Pubmed Central) - Jul 26, 2024
In addition, the MTB strains also showed relatively high rates of resistance against new and repurposed anti-TB drugs, with resistant rates of 2.4% (5/211) to delamanid and 1.9% (4/211) to bedaquiline...Genetic analysis revealed that the dominant mutations of isoniazid-, rifampin-, ethambutol-, levofloxacin-/moxifloxacin-, and ethionamide- resistance were katG_Ser315Thr(46.4%), rpoB_Ser450Leu (47.4%), embB_Met306Val (25.0%), gyrA_Asp94Ala (40.0%), and fabG1_c15t (42.9%), respectively...Our study offers crucial insights into the genetic diversity and drug-resistant profiles of TB strains circulating in Hinggan League. These findings are valuable for DR-TB surveillance and for guiding treatment regimens and public health interventions in the region.
- |||||||||| levofloxacin / Generic mfg.
Journal: Efficacy of sodium hypochlorite in overcoming antimicrobial resistance and eradicating biofilms in clinical pathogens from pressure ulcers. (Pubmed Central) - Jul 26, 2024
CRKP and MDRAB showed resistance to fluoroquinolones and carbapenems, while MRSA exhibited resistance to ?-lactams and levofloxacin...For planktonic C. albicans, the MIC90 was 0.150?mg/mL, and the MBEC90 was 0.250?mg/mL. These results highlight the challenge in treating biofilm-associated infections and underscore the potential of NaOCl as a robust antimicrobial agent against difficult-to-treat biofilm infections at concentrations lower than those typically found in commercial disinfectants.
- |||||||||| Journal, Adverse events: Clinical drug interactions between linezolid and other antibiotics: For adverse drug event monitoring. (Pubmed Central) - Jul 26, 2024
We found that the combinations of LZD and other antibiotics are related to multiple AEs, such as hepatotoxicity, drug resistance and electrocardiogram QT prolonged, but further research is still required to investigate their underlying mechanisms. This study can provide a new reference for the safety monitoring of LZD combined with other antibiotics in clinical practice.
- |||||||||| levofloxacin / Generic mfg.
Clinical, Journal: Prospective evaluation of thin-layer agar colour test in routine diagnosis of multidrug-resistant TB. (Pubmed Central) - Jul 26, 2024
The specificities for isoniazid and rifampicin DST were 97.3% and 98.0% for levofloxacin. The median time until a DST result was significantly shorter with CT than the BACTEC MGIT 960 system, 20 and 27 days, respectively, independent of the specimen type used.CONCLUSIONSThe CT is a highly accurate and fast initial diagnostic test for high-incidence settings and could also be used as a first culture and direct DST in peripheral settings..
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI
Trial completion date: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants (clinicaltrials.gov) - Jul 24, 2024
P=N/A, N=1600, Recruiting,
Experimental results demonstrate that the levofloxacin degradation kinetics constant in the CuMn-Sb-SnO2 system (0.188 Trial completion date: Sep 2024 --> Jul 2026
- |||||||||| levofloxacin / Generic mfg.
Journal: Pheromone cCF10 inhibits the antibiotic persistence of Enterococcus faecalis by modulating energy metabolism. (Pubmed Central) - Jul 23, 2024
h of levofloxacin hydrochloride (20?mg/mL) exposure, exhibiting a persistence rate of 0.109 %...The addition of cCF10 stimulated the Opp system and entered bacterial cells, inhibiting (p)ppGpp accumulation, thus maintaining the metabolically active state of bacteria and reducing persister cell generation. These findings offer valuable insights into the formation, as well as the control mechanism of E. faecalis persisters.
- |||||||||| levofloxacin / Generic mfg.
Journal: New proportion of levofloxacin citrate: Structural, physicochemical properties, and potency studies. (Pubmed Central) - Jul 23, 2024
This new solid-state salt was comparable with the established (1:1) molar ratio in solubility, stability, and potency, higher than LF alone. Hereafter, with a reduced CA portion, this new composition holds potential for further development in drug formulation as a stable, safer, and more efficient antibiotic.
- |||||||||| levofloxacin / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Biomarker, Journal, Next-generation sequencing: The polymicrobial nature of the oral cavity and claws of cats diagnosed by mass spectrometry and next-generation sequencing. (Pubmed Central) - Jul 22, 2024
Furthermore, three staphylococci harboring the methicillin resistance gene mecA were identified. We highlight the complexity of microorganisms inhabiting the oral/claw microbiotas of cats, the high resistance rate of the isolates to conventional antimicrobial agents, and the zoonotic risk of aggressions caused by bites and scratches from domestic cats.
- |||||||||| Journal: Position statement of the Spanish Society of Paediatric Infectious diseases on the diagnosis and treatment of Mycoplasma pneumoniae infection. (Pubmed Central) - Jul 18, 2024
Antibiotic treatment is justified in patients with risk factors for the development of severe disease (Down syndrome, anatomical or functional asplenia, immunosuppression), in hospitalized patients with respiratory infection and in patients with moderate or severe extrapulmonary forms. Taking into account aspects concerning the rational use of antimicrobials, the treatment of choice would be clarithromycin, with azithromycin as an alternative, reserving the use of doxycycline and levofloxacin for cases of antimicrobial resistance and/or infections of the central nervous system.
- |||||||||| TRENDS IN THE PRESCRIPTION OF ERADICATION TREATMENTS AND THEIR EFFECTIVENESS IN NAI?VE PATIENTS OVER 11 YEARS (2013-2023) IN EUROPE: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) (Poster Stage 5) - Jul 18, 2024 - Abstract #UEGW2024UEGW_2940;
This indicates that clarithromycin-based therapy can still be a reasonable treatment choice even in regions with high clarithromycin resistance rate, provided that pretreatment H. pylori antibiotic sensitivity is assessed. Prescriptions and effectiveness trends of first-line empirical treatments in Europe in the period 2013-2023.Year20132014201520162017201820192020202120222023TreatmentQuadruple-C+A+BSingle-capsule*Quadruple-M+Tc+BConcomitant-C+A+M/TSequential-C+A+M/TTriple-A+LTriple-A+MTriple-C+MTriple-C+A2.3%0.2%1.9%19.4%15.3%2.1%4.9%3.2%45.9%3.2%0.2%1.7%18.8%9.1%2.1%4.3%5.5%50.3%6.2%0.5%0.4%23.9%6.8%2.9%3.2%7.2%41.6%18.5%14.2%0.2%19.5%1.8%1.7%2.9%5.4%29.0%11.8%21.0%0.3%17.8%7.6%0.6%2.8%1.2%30.3%24.8%16.7%0.6%8.6%7.1%0.6%0.5%0.8%30.3%10.9%20.7%1.2%11.8%5.7%1.2%1.6%1.1%35.8%13.1%19.2%1.3%13.9%3.5%1.2%1.0%6.2%31.9%15.1%18.6%1.2%14.6%3.3%1.4%1.5%3.8%32.0%14.0%20.9%3.1%13.6%3.5%2.4%2.6%3.8%26.4%15.3%20.4%2.1%16.6%1.4%3.4%1.6%2.9%23.1%Therapy length7 days10 days14 days27.6%56.8%15.7%26.0%55.8%18.2%22.0%59.7%18.3%15.4%50.0%34.5%7.2%53.1%39.7%2.0%46.4%51.6%2.7%41.0%56.3%3.2%38.2%58.6%2.8%42.6%54.6%8.9%43.7%47.5%3.6%35.1%61.3%PPI doses**LowStandardHigh64.4%15.8%19.9%54.6%22.9%22.5%45.6%24.3%30.1%39.1%22.6%38.3%43.8%22.7%33.5%30.9%37.0%32.1%34.6%27.9%37.5%44.7%23.5%31.7%41.5%26.2%32.3%33.7%36.0%30.3%40.4%32.3%27.3%Overall effectivenessEradication rate (mITT)86.0%85.9%86.3%87.7%88.2%90.3%89.0%89.6%90.9%91.9%93.9%Effectiveness depending on geographical regionEastEast-CentreSouth-WestWest-CentreNorth91.5%87.4%84.2%88.7%83.8%80.5%84.9%86.8%92.1%84.4%85.2%85.2%86.0%92.9%85.6%82.9%84.7%89.8%94.3%86.5%81.4%86.1%91.3%89.1%86.6%91.3%88.2%90.6%92.4%77.5%89.5%89.6%88.4%91.4%83.0%92.0%93.1%86.1%89.9%82.5%92.9%91.5%91.0%88.3%82.1%91.5%91.7%93.5%93.8%83.7%93.1%95.4%95.3%92.5%81.9%PPI: proton pump inhibitor; mITT: modified intention-to-treat; A
- |||||||||| PHARMACOGENOMICS OF ANTIBIOTIC RESISTANCE IN HELICOBACTER PYLORI FROM COLOMBIA (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1301;
However, resistance rates for tetracycline and clarithromycin did not exceed the 10% threshold established in Colombia. The increased resistance rate of Helicobacter pylori to levofloxacin and amoxicillin may partially explain the therapeutic failures observed in Colombia.
- |||||||||| levofloxacin / Generic mfg., nitazoxanide / Generic mfg., moxifloxacin intravenous / Generic mfg.
LEVOFLOXACIN VERSUS MOXIFLOXACIN IN NITAZOXANIDE-BASED QUADRUPLE THERAPY AS A FIRST- AND SECOND-LINE TREATMENT FOR HELICOBACTER PYLORI INFECTION. A RANDOMIZED, COMPARATIVE, MULTICENTER STUDY (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1298;
Nai?ve patients were randomized into three groups according to treatment regimens: levofloxacin, nitazoxanide, doxycycline, and lansoprazole (LNDL); moxifloxacin, nitazoxanide, doxycycline, and lansoprazole (MNDL); or amoxicillin, clarithromycin, and lansoprazole (ACL) for 14 days. levofloxacin- and moxifloxacin-containing nitazoxanide-based regimens exhibit substantial efficacy for the eradication of both nai?ve and resistant H. pylori infections over a 14-day course with a considerable safety profile.
- |||||||||| EFFECTIVENESS OF EMPIRICAL FIRST-LINE H. PYLORI ERADICATION THERAPY IN ITALY FROM 2013 TO 2023: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1296;
levofloxacin- and moxifloxacin-containing nitazoxanide-based regimens exhibit substantial efficacy for the eradication of both nai?ve and resistant H. pylori infections over a 14-day course with a considerable safety profile. Among the first-line empiric treatments prescribed by the Italian centres participating in the Hp-EuReg, only single-capsule bismuth quadruple therapy with metronidazole-tetracycline-bismuth, sequential therapy with clarithromycin-amoxicillin-tinidazole, and non-bismuth concomitant therapy with clarithromycin-amoxicillin-tinidazole, achieved over 90% effectiveness.
|
